Rome: tackling repeat DNA for cancer, autoimmunity
Rome launches with $50M series A round to leverage repeat biology
GV-incubated Rome joins a growing cadre of companies targeting repeat biology, with plans to suppress repeat DNA-induced innate immune responses to treat autoimmune disorders and activate the same pathways for cancer.
Rome Therapeutics Inc. launched Monday with a $50 million series A round co-led by GV and Arch Venture Partners; Partners Innovation Fund also participated.
The company is going after proteins or peptides encoded by repeat sequences including endogenous retroviruses (ERVs), long interspersed nuclear elements (LINEs) and
